Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo

Contraception. 2008 Aug;78(2):113-9. doi: 10.1016/j.contraception.2008.04.001. Epub 2008 Jun 2.

Abstract

Background: The study was conducted to evaluate the efficacy and safety for the prevention of pregnancy of a 28-day oral contraceptive (OC) containing 150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days followed by 7 days of 10 mcg EE (Cette-28).

Study design: A 6-month, prospective, multicenter, single-arm study was conducted in 1302 women aged 18-45 years.

Results: Over six cycles of treatment, the cumulative risk of pregnancy among all treated subjects (n=1262) was 0.9%. The Pearl Index for women 18-35 years of age (n=1042) was 2.20, including 9 pregnancies with estimated conception dates during active drug ingestion or up to 7 days after the last combination tablet. The rate of unscheduled bleeding was low and the duration of scheduled bleeding was approximately 2 days during each of the six treatment cycles. The safety profile was similar to what has been reported for other OCs.

Conclusion: This low-dose, 28-day OC incorporating 7 days of 10 mcg EE during the hormone free interval is effective and safe for the prevention of pregnancy and is well-tolerated by women.

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Contraceptives, Oral, Sequential / administration & dosage*
  • Contraceptives, Oral, Sequential / adverse effects
  • Desogestrel / administration & dosage*
  • Desogestrel / adverse effects
  • Drug Administration Schedule
  • Ethinyl Estradiol / administration & dosage*
  • Ethinyl Estradiol / adverse effects
  • Female
  • Humans
  • Metrorrhagia / etiology
  • Pregnancy
  • Treatment Outcome

Substances

  • Contraceptives, Oral, Sequential
  • Ethinyl Estradiol
  • Desogestrel